Home > Press > MIT-Harvard CCNE Collaborator Awarded with Nobel Prize in Medicine
Abstract:
This year's Nobel Prize in Medicine was awarded to three scientists Drs. Jack W. Szostak, Elizabeth H. Blackburn and Carol W. Greider. The laureates have solved a major problem in biology: how the chromosomes can be copied in a complete way during cell divisions and how they are protected against degradation. The Nobel Laureates have shown that the solution is to be found in the ends of the chromosomes the telomeres and in an enzyme that forms them telomerase.
Dr. Szostak has ties to the NCI Alliance for Nanotechnology in Cancer through collaborations with Drs. Omid Farokhzad and Robert Langer at MIT-Harvard and the project dedicated to "Targeted Polymeric Nanoparticles for Cancer Therapeutic Applications". The goal of this project is to develop targeted polymeric nanoparticles for in vivo targeted delivery of cytotoxic, drug-encapsulated, controlled-release to cancer cells. This novel approach allows for a large amount of drug to be delivered to cancer cells and make it possible to reach a steady state cytotoxic drug concentration at the tumor site over an extended period of time. Dr. Szostak who is also a pioneer of aptamer technology has been involved in designing and optimizing the use of these novel classes of molecules for cancer therapy in support of CCNE project.
Learn more about the MIT-Harvard Center of Cancer Nanotechnology Excellence, here: nano.cancer.gov/action/programs/mit/
Read more about the 2009 Nobel Prize in Medicine winners, here: nobelprize.org/nobel_prizes/medicine/laureates/2009/index.html
####
About NCI Alliance for Nanotechnology in Cancer
The NCI Alliance for Nanotechnology in Cancer is catalyzing targeted discovery and development efforts that offer the greatest advances in the near and medium terms and to lower the barriers for those advances to be handed off to the private sector for commercial development.
For more information, please click here
Contacts:
NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 496-1550
Copyright © NCI Alliance for Nanotechnology in Cancer
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Govt.-Legislation/Regulation/Funding/Policy
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Single atoms show their true color July 5th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||